AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Alle Biotech-Start-ups sind aufgrund der hohen Zinsen seit Jahren rückläufig. Das soll sich nun ändern. Ein Biotech-Unternehmen wie Abcellera beurteilt man nicht nach seinem Umsatz, sondern nach seiner Pipeline. Und dann hat Abcellera ein einzigartiges Modell, das die Errungenschaften im Dunkeln lässt: die Entwicklung von Medikamenten für Dritte.

Wieviel Anteile hast?

https://aktien.guide/kursziel/AbCellera-Biologics-Inc-CA00288U1066

Unter 2$ zwar nicht. Aber WARUM ist es hier so extrem runter gerauscht? Teilweise gibt es Prognosen von 5-15$. Aber WARUM? Erschließt sich mir nicht so wirklich 🤷‍♂️ überlege mal mit ca. 1200 Stück einzusteigen 😅

https://aktienfinder.net/aktien-profil/AbCellera%20Biologics-Aktie#:~:text=AbCellera%20Biologics%20ist%20ein%20Biotechunternehmen,von%20verschiedenen%20Krankheiten%20zu%20identifizieren.

NAJA... Innerhalb des ausgewählten Zeitraums vom 11.12.2020 bis heute hat die AbCellera Biologics Aktie 95,2% verloren, was einer jährlichen Rendite von -56,3% entspricht. Langfristig hat der Kursverlauf somit enttäuscht. Mit Kursverlusten von 50,1% entwickelte sich die Aktie im laufenden Jahr ebenfalls nicht gut. Ihr Allzeithoch erreichte die AbCellera Biologics Aktie vor 44 Monaten am 11.12.2020 bei einem Kurs von 58,90 USD. Heute notiert die Aktie um 95,2% tiefer bei 2,85 USD.

Servus, was macht die Aktie bzw. das Unternehmen so interessant. Bitte erklärt es mir jemand ;) VG. Daniel

2024 als erstes Break-Even-Jahr erscheint mir möglich.

“The adMare team is proud to launch our third new well-funded company this fiscal year. Canada has already demonstrated its global leadership in radioisotope-based healthcare technologies, and we have unique infrastructure that provides a competitive advantage,” said Gordon C. McCauley, adMare President and CEO. “Our team has been working on the substance of Abdera for three years, and now we are ready to show why Canada and Abdera will become a world leader in developing related novel therapeutics.” TATs are a potentially transformative new class of drugs based on therapeutic antibodies armed with high-energy radioisotopes that emit alpha particles to selectively destroy cancer tumor cells. Abdera’s core technology comprises a proprietary and modular radioimmunoconjugate platform that is optimized to selectively deliver radioisotopes, including Actinium-225. Abdera will use its platform to enable the rapid development of a broad range of safe and efficacious therapies that will serve patients with limited treatment options. https://investors.abcellera.com/news/news-releases/2021/adMare-Launches-Abdera-with-AbCellera-as-a-Founding-Partner/default.aspx

2 sehr positive Nachrichten. Ich habe angekauft.: 1. The U.S. FDA cleared Abdera's Investigational New Drug (IND) application for ABD-147, and also granted it a Fast Track designation. AbCellera is a founding partner in Abdera, has a low-single-digit royalty stake in Abdera’s programs, and has a mid-single-digit equity ownership position. --> Oncology Isotopen auf Antibodies 2. On July 18, 2024, Invetx announced its upcoming acquisition by Dechra Pharmaceuticals for up to $520 million in total consideration. AbCellera is a founding partner in Invetx, has a low-single-digit royalty stake in Invetx’s programs, and has a mid-single-digit equity ownership position.--> mindestens 25 mln Einnahmen.

Wer nachkaufen möchte soll sich paar Wochen Gedulden

Morgen kommen die Quartalszahlen ich gebe euch Brief und siegel das der kurz danach unter 2 doller kommt

????? AbCellera price target lowered to $5 from $7 at KeyBanc TheFly Jul 11, 2024, 12:20 PM KeyBanc lowered the firm’s price target on AbCellera to $5 from $7 and keeps an Overweight rating on the shares. The firm’s credit card data continues to show healthy utilization levels across hospital systems post the Change Healthcare outage, with hospital customer levels up high single digits in May and June year over year, but the ongoing robust employment data for healthcare systems keeps the firm wary of potential spending for hospital-exposed names, the analyst tells investors in a research note.' https://www.tipranks.com/news/the-fly/abcellera-price-target-lowered-to-5-from-7-at-keybanc?mod=mw_quote_news#google_vignette

AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know Zacks Equity Research July 09, 2024 'For the fiscal year ending December 2024, this company is expected to earn -$0.60 per share, which is a change of -17.7% from the year-ago reported number. Analysts have been steadily raising their estimates for AbCellera Biologics. Over the past three months, the Zacks Consensus Estimate for the company has increased 7.4%.' https://www.zacks.com/stock/news/2298670/abcellera-biologics-abcl-upgraded-to-buy-heres-what-you-should-know?cid=CS-MKTWTCH-HL-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2298670&mod=mw_quote_news

AI Could Revolutionize Drug Discovery: A Look at Key Players Paul Hoffman Jul 08, 2024, 04:53 PM Story Highlights The future of AI-driven drug discovery looks promising as companies continue to progress in their clinical trials and partnerships. Artificial intelligence (AI) could have the potential to revolutionize drug discovery and bring new treatments to market, saving time and billions of dollars in research. This is because, currently, before any new drug gets full approval, it typically takes over a decade and, on average, over $1 billion to get to that point. However, the capabilities of AI in drug discovery have the potential to dramatically reduce this hurdle with the hope of making the process more efficient and effective. The companies that have taken the lead in dramatically altering the current structure by adopting AI-based drug discovery could be tomorrow’s overlooked big winners. Below, we’ll explore four leaders in this realm as we look at the specialization of Recursion Pharmaceuticals (NASDAQ:RXRX), AbCellera Biologics (NASDAQ:ABCL), Relay Therapeutics (NASDAQ:RLAY), and Schrodinger (NASDAQ:SDGR). All are being closely watched by analysts, as their clinical data readouts could significantly impact their stock valuations. AbCellera: Leveraging AI AbCellera leverages a vast database of immune cells and antibodies to identify drug candidates. The company has prioritized collaborative relationships with partners like Prelude Therapeutics (NASDAQ:PRLD), Incyte (NASDAQ:INCY), and Biogen (NASDAQ:BIIB). AbCellera’s internal research is in the early stages, with a program in metabolic and endocrine disease potentially leading to a first-in-class treatment. Piper Sandler (NYSE:PIPR) analyst Allison Bratzel remains optimistic, stating, “We like the long-term setup on this name.”

????: Regeneron Expects Earnings Hit After $24 Million R&D Charge Published: July 8, 2024 at 7:45 a.m. ET By Don Nico Forbes Regeneron Pharmaceuticals expects to incur an acquired in-process research and development charge of about $24 million in the second quarter, which should negatively impact earnings per share. The biotechnology company said the charge will likely hit net income per diluted share for the quarter by roughly 18 cents. Regeneron said the charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.